RCUS

Arcus Biosciences, Inc.

19.19 USD
+2.78 (+16.94%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Arcus Biosciences, Inc. stock is up 24.29% since 30 days ago. The next earnings date is May 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 83.33% of the previous 5 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
31 Jan 15:08 19 Apr, 2024 15.00 PUT 153 250
01 Feb 17:19 16 Feb, 2024 12.50 CALL 250 5898
07 Feb 16:32 15 Mar, 2024 12.50 CALL 100 9
07 Feb 16:49 15 Mar, 2024 12.50 CALL 370 9
07 Feb 17:06 15 Mar, 2024 12.50 CALL 110 9
07 Feb 20:25 16 Feb, 2024 12.50 CALL 427 5378
09 Feb 19:03 16 Feb, 2024 12.50 CALL 497 5274
09 Feb 19:04 16 Feb, 2024 12.50 CALL 90 5274
09 Feb 19:04 16 Feb, 2024 12.50 CALL 110 5274
12 Feb 19:16 15 Mar, 2024 20.00 PUT 75 0

About Arcus Biosciences, Inc.

Arcus Biosciences, Inc. develops and commercializes cancer therapies in the United States. Its product pipeline includes Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company was incorporated in 2015 and is headquartered in Hayward, California.

  • Wedbush
    Thu Feb 22, 08:22
    buy
    confirm
  • Wedbush
    Tue Jan 30, 10:42
    buy
    confirm
  • Mizuho
    Tue Jan 30, 09:34
    buy
    confirm